Vivo Capital, LLC Trevi Therapeutics, Inc. Transaction History
Vivo Capital, LLC
- $472 Million
- Q2 2025
A detailed history of Vivo Capital, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 4,487,903 shares of TRVI stock, worth $32.9 Million. This represents 5.2% of its overall portfolio holdings.
Number of Shares
4,487,903
Previous 3,487,903
28.67%
Holding current value
$32.9 Million
Previous $21.9 Million
11.9%
% of portfolio
5.2%
Previous 5.95%
Shares
3 transactions
Others Institutions Holding TRVI
# of Institutions
163Shares Held
109MCall Options Held
1.08MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$96.9 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$75.2 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$62.5 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$39 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY4.28MShares$31.4 Million0.01% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $428M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...